Novo Nordisk's Oral Semaglutide Diabetes Drug Shows No Greater Risk Of Heart Problems And Death Than Placebo; Oral Semaglutide Demonstrates Non-Inferiority To Placebo In Type 2 Diabetes Patients At High Risk Of Heart Problems